Effect Of PPARγ Rosiglitazone Agonists On PTEN Expression For The Treatment Of Vascular Restenosis

objective To examine the relationship between PTEN gene and vascular restenosis and to explore the effects and significance of PPAR-γagonists rosiglitazone on PTEN expression.Methods The experiment was performed at Animal Experimental Center of Shenzhen People's Hospital from January to March 2008.forty five male SPF SD rats weighing about 350g-400g were selected,and randomly divided into three group:control group,injury group and rosiglitazone group. injury group:rats'left carotid arteries were injuried by balloon catheter.Rats received physiological saline supplementation 3 days before injuried.rosiglitazone group:Rats received PPARγagonist rosiglitazone supplementation 3 days before left carotid arteries were injuried by balloon catheter. control group:rats'left carotid arteries were found but did not injury by balloon catheter,Rats received physiological saline supplementation 3 days before injuried.Rats were killed at 14 days after balloon denudation,the left injured carotid artery were harvested.The primary index The intimal thickness were detected by HE-staining,the expression of p-PTEN,PTEN,α-actin,PCNA were detected by immunohistochemistry and we use western blot to test the quality change of p-PTEN/PTEN expression apoptosis cell of carotid artery were detecte by tunnelResults①Rosiglitazone can significantly inhibit lumen restenosis(I/M:rosiglitazone group 0.399±0.102vs.injury group 1.540±0.058 P<0.05).②the expression of PTEN is mianly in endochylema,which is also expressed in cell nucleus.Rosiglitazone group had lower positive cell rate of PCNA than injury group(0.342±0.040 vs 0.455±0.035,P<0.05)③we found that the ratio of p-PTEN/PTEN in injury group is higher than control group(0.7153±.0822 vs.9815±.0533,P< 0.05).the ratio of p-PTEN/PTEN in rosiglitazone group is lower than injury group(0.9815±.0533 vs 0.7198±.0394,P<0.05).④Rosiglitazone group had higher apoptosis positive cell rate than injury group.(0.285±0.026 vs 0.190±0.020,P<0.05)。Conclusions There is a regulative mechanism in vascular restenosis,in which PTEN is an endogenous regulator.PPARγagonists rosiglitazone may attenuate restenosis by activating PTEN expression.